Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A pain management dashboard in the neonatal intensive care unit: anticipated barriers and facilitators of implementation among health care professionals.

JBI evidence implementation·2026

Same author

The Influence of Frailty on Pharmacotherapy Adherence and Adverse Drug Reactions in Older Psychiatric Patients.

Geriatrics (Basel, Switzerland)·2025

Same author

Fairy circles and temporal periodic patterns in the delayed plant-sulfide feedback model.

Mathematical biosciences and engineering : MBE·2024

Same author

Steady state distributions of moving particles in one dimension: with an eye towards axonal transport.

Journal of mathematical biology·2024

Same author

A stochastic framework for evaluating CAR T cell therapy efficacy and variability.

Mathematical biosciences·2024

Same author

Stochastic dynamics of human papillomavirus delineates cervical cancer progression.

Journal of mathematical biology·2023

Same journal

The hydra and hormetic effects in a single discrete-time overcompensation model.

Mathematical biosciences·2026

Same journal

Seasonal impacts on brucellosis transmission mediated by live sheep supply-demand dynamics.

Mathematical biosciences·2026

Same journal

Optimal controls and cost-effectiveness analysis on the transmission dynamics of early blight disease in tomatoes.

Mathematical biosciences·2026

Same journal

Temperature-dependent dynamics and allee effect thresholds mediate fourfold cusp stability in biological control of invasive vectors.

Mathematical biosciences·2026

Same journal

Dynamics of a stochastic tumor-immune interaction system with an Ornstein-Uhlenbeck process.

Mathematical biosciences·2026

Same journal

Post-peak dynamics and epidemic overshoot in SIR-type frameworks.

Mathematical biosciences·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 29, 2025

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Mathematical model for IL-2-based cancer immunotherapy.

Megan Dixon¹, Tuan Anh Phan², J C Dallon¹

¹Department of Mathematics, Brigham Young University, Provo, UT 84602, USA.

Mathematical Biosciences

|April 4, 2024

Summary

This summary is machine-generated.

This study models IL-2 cancer immunotherapy, finding that T cell death rates and IL-2 dose determine tumor size. Intermittent IL-2 administration may effectively control tumor growth.

Keywords:

CD4(＋) T cell CD8(＋) T cell IL-2 Immunotherapy

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Related Experiment Videos

Last Updated: Jun 29, 2025

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Area of Science:

Immunology
Mathematical Biology
Computational Science

Background:

Interleukin-2 (IL-2) is a cytokine used in cancer immunotherapy.
Understanding the dynamics of T cell populations (CD4+ and CD8+) is crucial for effective IL-2 therapy.
Mathematical modeling provides a framework to predict treatment outcomes.

Purpose of the Study:

To develop and analyze a mathematical model for IL-2-based cancer immunotherapy.
To identify key parameters influencing the efficacy of IL-2 treatment.
To explore the impact of different IL-2 dosing strategies on tumor size and T cell populations.

Main Methods:

Development of a basic mathematical model simulating IL-2 immunotherapy.
Analysis of model parameters including T cell death rates and IL-2 dose.
In silico clinical trials to evaluate short-term treatment behaviors.

Main Results:

Therapy outcome is determined by CD4+ T cell death rate, CD8+ T cell death rate, and IL-2 dose.
Minimal tumor size is achievable with high IL-2 doses if CD4+ T cells are eliminated.
If T cells persist, final tumor size is independent of IL-2 dose and depends on CD4+ T cell death rate.
IL-2 can slow CD4+ T cell proliferation and transiently increase CD8+ T cells.
Intermittent IL-2 administration shows potential for sustained tumor suppression.

Conclusions:

The relative death rates of CD4+ and CD8+ T cells, along with IL-2 dosage, are critical factors in cancer immunotherapy outcomes.
Intermittent IL-2 administration may be a promising strategy for long-term tumor size control.
Mathematical modeling is valuable for optimizing immunotherapy protocols.